KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Accumulated Expenses (2018 - 2025)

Castle Biosciences' Other Accumulated Expenses history spans 7 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 11.81% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $8.9 million, up 11.81%, while the annual FY2025 figure was $8.9 million, 11.81% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $8.9 million at Castle Biosciences, up from $8.9 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $8.9 million in Q4 2025 and bottomed at $2.0 million in Q1 2021.
  • The 5-year median for Other Accumulated Expenses is $7.0 million (2023), against an average of $6.4 million.
  • The largest annual shift saw Other Accumulated Expenses soared 223.84% in 2022 before it fell 10.51% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $5.7 million in 2021, then fell by 7.33% to $5.3 million in 2022, then soared by 39.05% to $7.3 million in 2023, then grew by 9.24% to $8.0 million in 2024, then rose by 11.81% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Other Accumulated Expenses are $8.9 million (Q4 2025), $8.9 million (Q3 2025), and $8.2 million (Q2 2025).